Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells

被引:132
|
作者
Zhao, Yong [1 ]
Jiang, Zhaoshun [2 ]
Zhao, Tingbao [3 ]
Ye, Mingliang [4 ]
Hu, Chengjin [5 ]
Yin, Zhaohui [2 ]
Li, Heng [6 ]
Zhang, Ye [4 ,7 ]
Diao, Yalin [4 ]
Li, Yunxiang
Chen, Yingjian [5 ]
Sun, Xiaoming [5 ]
Fisk, Mary Beth [8 ]
Skidgel, Randal [9 ]
Holterman, Mark [10 ]
Prabhakar, Bellur [11 ]
Mazzone, Theodore [1 ]
机构
[1] Univ Illinois, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60612 USA
[2] Gen Hosp Jinan Mil Command, Endocrinol Sect, Jinan 250031, Shandong, Peoples R China
[3] Gen Hosp Jinan Mil Command, Stem Cell Treatment Ctr, Jinan 250031, Shandong, Peoples R China
[4] Gen Hosp Jinan Mil Command, Sect Blood Transfus, Jinan 250031, Shandong, Peoples R China
[5] Gen Hosp Jinan Mil Command, Sect Mol Diagnost, Jinan 250031, Shandong, Peoples R China
[6] Jinan Cent Hosp, Sect Neuronol, Jinan 250020, Shandong, Peoples R China
[7] Jinan Tianhe Stem Cell Biotechol Co Ltd, Jinan 250055, Shandong, Peoples R China
[8] Texas Cord Blood Bank, San Antonio, TX 78201 USA
[9] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA
[10] Univ Illinois, Dept Surg, Peoria, IL 61603 USA
[11] Univ Illinois, Dept Immunol & Microbiol, Chicago, IL 60612 USA
来源
BMC MEDICINE | 2012年 / 10卷
关键词
REGULATORY T-CELLS; CUTTING EDGE; DOUBLE-BLIND; C-REL; TOLERANCE; THERAPY; CD28; GAD; MECHANISMS; UNIQUE;
D O I
10.1186/1741-7015-10-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Inability to control autoimmunity is the primary barrier to developing a cure for type 1 diabetes (T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clones offers promise for a new approach to overcome the autoimmunity underlying T1D. Methods: We developed a procedure for Stem Cell Educator therapy in which a patient's blood is circulated through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them to the patient's circulation. In an open-label, phase1/phase 2 study, patients (n = 15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years (range: 15 to 41), and median diabetic history was 8 years (range: 1 to 21). Results: Stem Cell Educator therapy was well tolerated in all participants with minimal pain from two venipunctures and no adverse events. Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks. However, participants in the Control Group (n = 3) did not exhibit significant change at any follow-up. Individuals who received Stem Cell Educator therapy exhibited increased expression of co-stimulating molecules (specifically, CD28 and ICOS), increases in the number of CD4(+)CD25(+)Foxp3(+) Tregs, and restoration of Th1/Th2/Th3 cytokine balance. Conclusions: Stem Cell Educator therapy is safe, and in individuals with moderate or severe T1D, a single treatment produces lasting improvement in metabolic control. Initial results indicate Stem Cell Educator therapy reverses autoimmunity and promotes regeneration of islet beta cells. Successful immune modulation by CB-SCs and the resulting clinical improvement in patient status may have important implications for other autoimmune and inflammation-related diseases without the safety and ethical concerns associated with conventional stem cell-based approaches.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells
    Yong Zhao
    Zhaoshun Jiang
    Tingbao Zhao
    Mingliang Ye
    Chengjin Hu
    Zhaohui Yin
    Heng Li
    Ye Zhang
    Yalin Diao
    Yunxiang Li
    Yingjian Chen
    Xiaoming Sun
    Mary Beth Fisk
    Randal Skidgel
    Mark Holterman
    Bellur Prabhakar
    Theodore Mazzone
    BMC Medicine, 10
  • [3] Targeting Insulin Resistance via the Immune Modulation of Cord Blood-Derived Multipotent Stem Cells by the Stem Cell Educator Therapy
    Zhao, Yong
    Jiang, Zhaoshun
    Ye, Mingliang
    Yin, Zhaohui
    Li, Heng
    Diao, Yalin
    Holterman, Mark
    Mazzone, Theodore
    DIABETES, 2012, 61 : A75 - A75
  • [4] Targeting Insulin Resistance in Type 2 Diabetes via Immune Modulation of Cord Blood-Derived Multipotent Stem Cells (CB-SCs) in Stem Cell Educator Therapy
    Zhao, Yong
    Jiang, Zhaoshun
    Yin, Zhaohui
    Zhang, Ye
    Shen, Jie
    Zhao, Tingbao
    Ye, Mingliang
    Diao, Yalin
    Li, Yunxiang
    Thaker, Hatim
    Jain, Summit
    Li, Heng
    DIABETES, 2013, 62 : A263 - A263
  • [5] Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
    Zhao, Yong
    Jiang, Zhaoshun
    Zhao, Tingbao
    Ye, Mingliang
    Hu, Chengjin
    Zhou, Huimin
    Yin, Zhaohui
    Chen, Yana
    Zhang, Ye
    Wang, Shanfeng
    Shen, Jie
    Thaker, Hatim
    Jain, Summit
    Li, Yunxiang
    Diao, Yalin
    Chen, Yingjian
    Sun, Xiaoming
    Fisk, Mary Beth
    Li, Heng
    BMC MEDICINE, 2013, 11
  • [6] Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
    Yong Zhao
    Zhaoshun Jiang
    Tingbao Zhao
    Mingliang Ye
    Chengjin Hu
    Huimin Zhou
    Zhaohui Yin
    Yana Chen
    Ye Zhang
    Shanfeng Wang
    Jie Shen
    Hatim Thaker
    Summit Jain
    Yunxiang Li
    Yalin Diao
    Yingjian Chen
    Xiaoming Sun
    Mary Beth Fisk
    Heng Li
    BMC Medicine, 11
  • [7] Released Exosomes Contribute to the Immune Modulation of Cord Blood-Derived Stem Cells
    Hu, Wei
    Song, Xiang
    Yu, Haibo
    Sun, Jingyu
    Zhao, Yong
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [8] Analysis of cytokines in umbilical cord blood-derived multipotent stem cell
    Hwang, Soo Han
    Kim, Mi Ho
    Yang, Il Ho
    Bahk, Jong Yoon
    Han, Hoon
    BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 2007, 12 (01) : 32 - 38
  • [9] Analysis of cytokines in umbilical cord blood-derived multipotent stem cell
    Soo Han Hwang
    Mi Ho Kim
    Il Ho Yang
    Jong Yoon Bahk
    Hoon Han
    Biotechnology and Bioprocess Engineering, 2007, 12 : 32 - 38
  • [10] Utilization of Purified Autologous Peripheral Blood-Derived Stem Cells, Combined With Immune Modulation by Cord Blood Mesenchymal Stem Cells in Treatment of Type 1 Diabetes Mellitus: A Jordanian Pilot Study
    Al-Zoubi, Adeeb
    Haboob, Hazem
    Al-Bakheet, Sameh
    Tapponi, Marwa
    Zalloum, Mahasen
    Abu Radi, Samer
    Khalifeh, Farah
    Sarayrah, Shahed
    AlTwal, Feras
    Hermas, Jamil
    El-Khateeb, Mohammed
    Holterman, Mark
    TRANSFUSION, 2015, 55 (06) : 2A - 3A